NGS for unknown primary – pro
NGS can provide information taht can better characterize the cancer type and sometimes make ti possible to identify the primary cancer, which leads to better treatment planning. Unless patients with cancer of unknown primary site (CUP) have other factors working for them, many have poor survival time using platinum-taxane chemotherapeutics, with a median overall survival (OS) of just 6 to 12 months.
NCCN recommends NGS testing to identify actionalbe mutations and says: “Consdier NGS in patients based on clinicopathological features and where it guides therapeutic decision making.
Hayashi H, Takiguchi Y, Minami H, et al. Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site: a nonrandomized phase 2 clinical trial. JAMA Oncol. Published online October 15, 2020. doi:10.1001/jamaoncol.2020.4643
NCCN OCC-2, 2021